Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 2
1967 2
1968 1
1971 1
1973 1
1974 2
1976 1
1977 4
1978 1
1979 2
1983 1
1984 4
1985 2
1987 3
1988 2
1989 3
1990 2
1991 1
1992 3
1993 5
1994 3
1995 2
1996 2
1997 3
1998 4
1999 2
2000 1
2001 1
2002 5
2003 8
2004 1
2006 3
2007 3
2008 8
2009 4
2010 5
2011 5
2012 8
2013 8
2014 8
2015 6
2016 11
2017 9
2018 9
2019 4
2020 8
2021 6
2022 2
2023 3
2024 8
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W. Bowman SJ, et al. Among authors: papas a. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30. Lancet. 2022. PMID: 34861168 Clinical Trial.
Réduction des risques en addictologie.
Papas A. Papas A. Rev Infirm. 2018 Jan;67(237):15. doi: 10.1016/j.revinf.2017.11.001. Rev Infirm. 2018. PMID: 29331184 French. No abstract available.
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T, Kaul M, Szántó A, Tseng JC, Papas AS, Pylvaenaeinen I, Hanser M, Abdallah N, Grioni A, Santos Da Costa A, Ferrero E, Gergely P, Hillenbrand R, Avrameas A, Cenni B, Siegel RM. Dörner T, et al. Among authors: papas as. Ann Rheum Dis. 2024 Feb 15;83(3):360-371. doi: 10.1136/ard-2023-224691. Ann Rheum Dis. 2024. PMID: 37932009 Free PMC article. Clinical Trial.
CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.
St Clair EW, Baer AN, Ng WF, Noaiseh G, Baldini C, Tarrant TK, Papas A, Devauchelle-Pensec V, Wang L, Xu W, Pham TH, Sikora K, Rees WA, Alevizos I. St Clair EW, et al. Among authors: papas a. Nat Med. 2024 Jun;30(6):1583-1592. doi: 10.1038/s41591-024-03009-3. Epub 2024 Jun 5. Nat Med. 2024. PMID: 38839899 Free PMC article. Clinical Trial.
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Coxib and traditional NSAID Trialists' (CNT) Collaboration; Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Coxib and traditional NSAID Trialists' (CNT) Collaboration, et al. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30. Lancet. 2013. PMID: 23726390 Free PMC article.
Prévenir la perte de sens au travail.
Papas A. Papas A. Rev Infirm. 2016 Nov;65(225):1. doi: 10.1016/j.revinf.2016.09.004. Rev Infirm. 2016. PMID: 27968961 French. No abstract available.
L'amputation en contexte post-traumatique.
Papas A, Warnet S. Papas A, et al. Rev Infirm. 2015 Mar;209:15. doi: 10.1016/j.revinf.2014.12.005. Rev Infirm. 2015. PMID: 26145127 French. No abstract available.
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W; TWINSS study group. Fisher BA, et al. Among authors: papas a. Lancet. 2024 Aug 10;404(10452):540-553. doi: 10.1016/S0140-6736(24)01211-X. Epub 2024 Jul 31. Lancet. 2024. PMID: 39096929 Clinical Trial.
Le refus de soins.
Papas A. Papas A. Rev Infirm. 2016 Oct;224:15. doi: 10.1016/j.revinf.2016.08.015. Rev Infirm. 2016. PMID: 27719785 French. No abstract available.
182 results